Diagnosing central nervous system rubeola (measles) virus infection and/or subacute sclerosing panencephalitis
Immunofluorescence Assay (IFA)
Measles Virus
Rubeola Antibodies, IgG and IgM (Separate Determinations), Spinal Fluid
CSF
Container/Tube: Sterile vial
Specimen Volume: 0.25 mL
If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.
0.1 mL
Gross hemolysis | OK |
Gross lipemia | OK |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
CSF | Refrigerated (preferred) | 14 days | |
Frozen | 14 days |
Diagnosing central nervous system rubeola (measles) virus infection and/or subacute sclerosing panencephalitis
Measles is a serious and highly contagious disease that can be a leading cause of death where nutrition and sanitation are limited. Onset begins with cough, fever, and lymphadenopathy approximately 2 weeks after exposure. Diagnosis is usually made when the rash appears. Koplik spots may be seen earlier on the buccal mucosa. Complications of measles may develop in children who appear to have normal immune functions.
Persistent infection of the central nervous system with measles virus is recognized to cause the disease subacute sclerosing panencephalitis (SSPE). SSPE is a rare, late complication of measles with an incidence of approximately 1 per 100,000 cases. SSPE is a progressive, usually fatal disease that occurs most often in children between the ages of 5 and 14 years. The onset is insidious and progressive. The incubation period from acute measles to onset of neurological symptoms varies from several months to many years. One of the most useful diagnostic tests involves the measurement of measles-specific antibodies in the cerebrospinal fluid (CSF) of patients with SSPE. Levels of antibody are significantly elevated in the CSF of SSPE patients compared to those without the disease.
IgG: <1:5
IgM: <1:10
Reference values apply to all ages.
Detection of organism-specific antibodies in the cerebrospinal fluid (CSF) may suggest central nervous system infection. However, these results are unable to distinguish between intrathecal antibodies and serum antibodies introduced into the CSF at the time of lumbar puncture or from a breakdown in the blood-brain barrier. The results should be interpreted with other laboratory and clinical data prior to a diagnosis of central nervous system infection.
Patients with subacute sclerosing panencephalitis have serum antibody titers that are 10 to 100 times higher than those seen in late convalescent-phase sera. More importantly, there is pronounced local production of oligoclonal measles virus antibodies in the central nervous system.
Detection of organism-specific antibodies in the cerebrospinal fluid (CSF) may suggest central nervous system infection. However, these results are unable to distinguish between intrathecal antibodies and serum antibodies introduced into the CSF at the time of lumbar puncture or from a breakdown in the blood-brain barrier. The results should be interpreted with other laboratory and clinical data prior to a diagnosis of central nervous system infection.
1. Gascon GG: Subacute sclerosing panencephalitis. Semin Pediatr Neurol. 1996 Dec;3(4):260-269
2. Gershon AA: Measles virus (Rubeola). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2110-2116
Cerebrospinal fluid (CSF) from a patient is reacted with the antigen substrate. Antibodies, if present, will bind to the antigen forming stable antigen-antibody complexes. If no antibodies are present, the complexes will not be formed and CSF components will be washed away. Fluorescein labeled antihuman IgG or IgM antibody is added to the reaction site which binds with the complexes formed. This results in a positive reaction of bright apple-green fluorescence when viewed with a properly equipped fluorescence microscope. If no complexes are formed, the fluorescein labeled antibody will be washed away, exhibiting a negative result.(Package insert: Measles Virus Antigen Substrate Slide. AESKU.BION, 9/2019)
Monday through Friday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
86765 x 2
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
ROC | Rubeola (Measles) Ab, IgG,IgM, CSF | 90254-4 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
5741 | Rubeola (Measles) Ab, IgG | 22501-1 |
5742 | Rubeola (Measles) Ab, IgM | In Process |